Celldex to present results from CDX-301 Phase 1 research in healthy volunteers Celldex Therapeutics.

Celldex to present results from CDX-301 Phase 1 research in healthy volunteers Celldex Therapeutics, Inc. today announced the next data display at the American Society of Hematology 54th Annual Meeting and Exposition to be held in Atlanta, GA from December 8 through December 11, 2012. Results from a Phase 1 study of Celldex's candidate CDX-301 will be presented in a poster program entitled A Phase 1 Trial of the Hematopoietic Development Aspect CDX-301 in Healthy Volunteers on Mon, 10 December, 2012 from 6:00 pm to 8:00 pm ET.Patents 6,838,248, entitled Compositions and Options for Detecting Pre-Cancerous Circumstances in Cell and Cells Samples Using 5, 10, 15, 20-Tetrakis Porphine and 7,384,764, entitled Options for Prognosing Response to Malignancy Therapy with 5, 10, 15, 20-Tetrakis Porphine protect the technique of detecting cancerous circumstances and prognosing responses to cancers therapy with TCPP. Email address details are in comparison to CT Pap and scans staining go through by independent radiologists and cytopathologists, respectively, to confirm precision.